SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada
Milestone Coincides with SK Biopharmaceuticals' Global Plan Expanding Cenobamate Access to More Than 100 Markets Worldwide SEOUL, South Korea and ROME, March 12, 2024 /PRNewswire/ -- SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CN...
SK Life Science Labs, a Subsidiary of SK Biopharmaceuticals, Presents Discovery of Oral SMARCA2 Degraders Data at 6th Annual Targeted Protein Degradation Summit
Preclinical data show SK Life Science Labs compounds have robust anti-tumor efficacy in vivo and oral leads have demonstrated potent selective degradation of SMARCA2 with selective inhibition of proliferation of SMARCA4 mutant cells KING OF PRUSSIA, Pa., Oct. 31, 2023 /PRNewswire/ -- SK Life Scie...
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
New data presented on novel orally bioavailable p300-selective degraders showing significant anti-tumor activity in preclinical models of androgen receptor (AR) positive prostate cancer SEOUL, South Korea and KING OF PRUSSIA, Pa., Oct. 12, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global bio...
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and MOPED™ Molecular Glue Screening Platform at the 20th Annual Discovery on Target Conference
These are the first in a series of presentations scheduled through the end of the year sharing advances to SK Biopharmaceutical's targeted protein degradation (TPD) pipeline SEOUL, South Korea and KING OF PRUSSIA, Pa., Sept. 26, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech focuse...
SK Biopharmaceuticals Assembles 'Board of Prominent Experts' to Boost Growth, Innovation
Renowned oncologist Yung-Jue Bang, M.D., Ph.D., chairs the distinguished 5-member Scientific Advisory Board to further advance SK Biopharmaceuticals as a global big biotech SEOUL, South Korea, Aug. 2, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech company, announced the formation o...
SK Biopharmaceuticals Makes Big Bets to be 'Big Biotech'
SK Biopharmaceuticals CEO Donghoon Lee maps out its medium to long-term strategy at a press conference SK Biopharmaceuticals mobilizes its cutting-edge modality platforms of radiopharmaceutical therapy (RPT), targeted protein degradation (TPD), and cell and gene therapy (CGT) aligning with its v...
SK Biopharmaceuticals Wins Red Dot Design Award for Wearable Devices
* 'Zero WiredTM' and 'Zero EarbudsTM' named 'Winners' in the healthcare category for outstanding product design * SK Biopharmaceuticals' wearable devices earn a global accolade once again following the CES® Innovation Awards SEOUL, South Korea, April 10, 2023 /PRNewswire/ -- SK Biopharmaceuti...
SK Biopharmaceuticals to Present Future Plan for Global Investors, Partners at 'SK Bio Night'
SK Inc.'s 1st SK Bio Night on the sidelines of J.P. Morgan Healthcare Conference offers a glimpse into the future of its global business in new drug, CDMO, biotech SK Biopharmaceuticals joins SK Inc.'s Bio Investment Center, SK pharmteco, or 'SK bio family,'for potential investment, partnerships...
SK Biopharmaceuticals CEO Donghoon Lee Buys 3,000 Shares of Company Stock
- CEO shows commitment and confidence in the company's future through share purchase PANGYO, South Korea, Jan. 5, 2023 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, today announced that Mr.Donghoon Lee, the Chief Executive Officer and President of SK Biophar...
SK Biopharmaceuticals Unveils Vision for Digital Healthcare
SK Biopharmaceuticals aims to become a 'total healthcare solution provider' as it strengthens its digital business ecosystem under 'Project ZeroTM' SK Biopharmaceuticals plans to showcase wearable devices, including CES® 2023 Innovation Awards winners'Zero GlassesTM,' 'Zero WiredTM' at the world'...
SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France
Cenobamate (ONTOZRY®), for the treatment of uncontrolled focal-onset seizures in adults, is now available in 5 major European countries –Germany, the UK, Italy, Spain, France – and 10 other key markets PANGYO, South Korea, Dec. 8, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global ...
SK Biopharmaceuticals Wins Export Award for Cenobamate
SK Biopharmaceuticals receives the '$100 million Export Tower' award, becoming the first Korean pharmacompany to earn this prestige with a single innovative anti-seizure medication, cenobamate Cenobamate achieves over $100 million in exports in two years after launching in the U.S. andEurope – t...
Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals' Seizure Detection Wearable Device at AES 2022
Poster session features a preliminary study result of potential seizure monitoring and detection for patients using SK Biopharmaceuticals' wearable device SK Biopharmaceuticals, Seoul National University Bundang Hospital plan to use Zero WiredTM to further pursue clinical research and develop it...
SK Biopharmaceuticals Names Donghoon Lee, Head of Bio Investment Center of SK Inc., as New CEO
Mr. Lee brings expertise in global new biz development to further strengthen SK Biopharmaceuticals as SK Group's key bio business PANGYO, South Korea, Nov. 30, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that it has named Mr. Donghoon Lee, Ex...
SK Biopharmaceuticals Named CES 2023 Innovation Awards Honoree
SK Biopharmaceuticals is recognized in the digital health category for two wearable devices –Zero Glasses TM and Zero Wired TM – becoming the first Korean pharma to earn this accolade PANGYO, South Korea, Nov. 16, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical co...
SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969
State-run financing to provide two-year support of Phase 1 research for oncology candidate, SKL27969, for the potential treatment of advanced solid tumors SK Biopharmaceuticals to present preclinical data on oncology candidate, SKL27969, at Society for Neuro-Oncology Conference PANGYO, South Ko...
